Uy Ear
Stock Analyst at Mizuho
(3.62)
# 850
Out of 4,996 analysts
69
Total ratings
41.46%
Success rate
11.54%
Average return
Main Sectors:
Stocks Rated by Uy Ear
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QURE uniQure | Maintains: Outperform | $30 → $60 | $54.31 | +10.48% | 5 | Sep 25, 2025 | |
| MBX MBX Biosciences | Maintains: Outperform | $38 → $56 | $17.51 | +219.82% | 2 | Sep 24, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Neutral | $23 → $24 | $21.05 | +14.01% | 14 | Aug 7, 2025 | |
| SRPT Sarepta Therapeutics | Downgrades: Neutral | $40 → $14 | $18.36 | -23.75% | 8 | Jul 21, 2025 | |
| TECX Tectonic Therapeutic | Maintains: Outperform | $51 → $85 | $15.20 | +459.21% | 2 | May 15, 2025 | |
| ARQT Arcutis Biotherapeutics | Maintains: Outperform | $20 → $21 | $17.57 | +19.52% | 14 | Feb 26, 2025 | |
| RLMD Relmada Therapeutics | Downgrades: Neutral | $23 → $1 | $1.81 | -44.75% | 1 | Dec 5, 2024 | |
| ALKS Alkermes | Maintains: Outperform | $35 → $40 | $27.89 | +43.42% | 5 | Nov 13, 2024 | |
| RNAC Cartesian Therapeutics | Initiates: Buy | $40 | $9.26 | +331.97% | 1 | May 24, 2024 | |
| EOLS Evolus | Maintains: Buy | $20 → $23 | $5.99 | +284.29% | 3 | Mar 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $116 → $140 | $142.00 | -1.41% | 10 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $40 | $179.71 | -77.74% | 1 | Jun 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $2.36 | +323.73% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $3 | $1.46 | +105.48% | 2 | Mar 1, 2023 |
uniQure
Sep 25, 2025
Maintains: Outperform
Price Target: $30 → $60
Current: $54.31
Upside: +10.48%
MBX Biosciences
Sep 24, 2025
Maintains: Outperform
Price Target: $38 → $56
Current: $17.51
Upside: +219.82%
ACADIA Pharmaceuticals
Aug 7, 2025
Maintains: Neutral
Price Target: $23 → $24
Current: $21.05
Upside: +14.01%
Sarepta Therapeutics
Jul 21, 2025
Downgrades: Neutral
Price Target: $40 → $14
Current: $18.36
Upside: -23.75%
Tectonic Therapeutic
May 15, 2025
Maintains: Outperform
Price Target: $51 → $85
Current: $15.20
Upside: +459.21%
Arcutis Biotherapeutics
Feb 26, 2025
Maintains: Outperform
Price Target: $20 → $21
Current: $17.57
Upside: +19.52%
Relmada Therapeutics
Dec 5, 2024
Downgrades: Neutral
Price Target: $23 → $1
Current: $1.81
Upside: -44.75%
Alkermes
Nov 13, 2024
Maintains: Outperform
Price Target: $35 → $40
Current: $27.89
Upside: +43.42%
Cartesian Therapeutics
May 24, 2024
Initiates: Buy
Price Target: $40
Current: $9.26
Upside: +331.97%
Evolus
Mar 8, 2024
Maintains: Buy
Price Target: $20 → $23
Current: $5.99
Upside: +284.29%
Feb 8, 2024
Maintains: Neutral
Price Target: $116 → $140
Current: $142.00
Upside: -1.41%
Jun 7, 2023
Maintains: Buy
Price Target: $36 → $40
Current: $179.71
Upside: -77.74%
Mar 17, 2023
Reiterates: Buy
Price Target: $10
Current: $2.36
Upside: +323.73%
Mar 1, 2023
Maintains: Buy
Price Target: $5 → $3
Current: $1.46
Upside: +105.48%